Sacituzumab Govitecan for mTNBC: A Review of Real-World Efficacy and Safety Data
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Paolo Tarantino, MD Sacituzumab govitecan is a TROP-2 antibody drug conjugate approved for patients with metastatic triple-negative breast cancer (mTNBC) based on findings from the ASCENT study. But how is this treatment approach performing in the real world? Joining Dr. Charles Turck to share a study’s findings on the real-world efficacy and safety of sacituzumab govitecan is Dr. Paolo Tarantino, medical oncologist and advanced research fellow in the Breast Oncology Program at Dana-Farber Cancer Institute and Harvard Medical School.